Across TCGA pan-cancer cohorts, LIN28A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LIN28A data layer compared with 20 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LIN28A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LIN28A expression acts as an unfavorable survival marker.
CCRCC and PDAC are the cancer types where LIN28A mass-spec protein most reproducibly stratifies survival.